Skip to main content
. 2011 Sep 29;13(5):R95. doi: 10.1186/bcr3020

Table 1.

Phenotypic characterization of breast tumors derived from BRCA2 germline mutation carriers

Biomarkers for definition of phenotypes 0 I-II III
ER 8 (25%) 7 (22%) 17 (53%)
PR 12 (37%) 14 (44%) 6 (19%)
HER2 22 (69%) 10 (31%) 0 (0)
Cellular proliferation; The proportion of cells positive for Ki-67
Ki-67 0-14% (1st Qu.) > 14%-35% (IQR) > 35% (3rd Qu.)
Luminal 8 (33%) 14 (58%) 2 (8%)
Triple-negative 0 (0) 3 (37%) 5 (63%)
Χ2 test; P = 0.004
Expression of basal features
EGFR 0 I ≥ II
Luminal 22 (96%) 1 (4%) 0 (0)
Triple-negative 4 (50%) 1 (13%) 3 (37%)
Χ2 test; P = 0.004
CK5/6 Negative Positive
Luminal 24 (100%) 0
Triple-negative 3 (37%) 5 (63%)
Χ2 test; P = 0.0003
pRb/p16 pathway
p16 (CDKN2A) 0 I-II III
Luminal A 3 (38%) 4 (50%) 1 (12%)
Luminal B 9 (60%) 5 (33%) 1 (7%)
Triple-negative 0 1 (12%) 7 (88%)
Χ2 test; P = 0.0007
Cyclin-D1 (CCND1) 0-15% (1st Qu.) > 15%-75% (IQR) > 75% (3rd Qu.)
Luminal A 1 (12%) 4 (50%) 3 (38%)
Luminal B 1 (6%) 8 (50%) 7 (44%)
Triple-negative 6 (75%) 2 (25%) 0
Χ2 test; P = 0.005
pRb (RB1) 0 (Negative) I (Positive)
Luminal A 1 (13%) 7 (87%)
Luminal B 2 (13%) 14 (87%)
Triple-negative 4 (50%) 4 (50%)
Χ2 test; P = 0.085
Morphologic features
Histologic grade I II III
Luminal 2 (8%) 11 (44%) 12 (48%)
Triple-negative 1 (12%) 1 (12%) 6 (75%)
Χ2 test, P = 0.27